Products
Imatinib
Pharmacotherapeutic group
Antineoplastic drug, tyrosine kinase inhibitorInternational name
ImatinibDosage form
film-coated tabletsTyrosine kinase inhibitor. It inhibits Bcr-Abl tyrosine kinase at the cellular level, in vitro and in vivo. The compound selectively inhibits proliferation and induces apoptosis in Bcr-Abl positive cell lines as well as fresh leukaemic cells from Philadelphia chromosome positive CML and acute lymphoblastic leukaemia patients.
Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor and stem cell factor, and inhibits cellular events mediated by them.